BioInvent International: BioInvent Selected to The Leukemia

Strategic equity investment of USD 3 million to support clinical advancement of BI-1206 in Non-Hodgkin's LymphomaSupports also clinical development of BI-1808 in cutaneous T-cell lymphomaLLS TAP is a strategic

Related Keywords

Stockholm , Sweden , Martin Welschof , Bioinvent Internationalview , Cecilia Hofvander , Instagram , Twitter , Leukemia Lymphoma Society , Bioinvent International , Bioinvent International Ab Nasdaq Stockholm , Leukemia Lymphoma Society Therapy Acceleration Program , Facebook , Therapy Acceleration Program , Nasdaq Stockholm , Lymphoma Society , Lore Gruenbaum , Vice President , Senior Director Investor , Bioinvent , Nternational , Elected , Leukemia , Lymphoma , Society , Therapy , Acceleration , Program , Eceives , Billion , Strategic , Equity , Investment ,